800-845-6913
Tuteur & Associates, LLC | Knowledge is Power.
Click the arrow to start the video.
The full Trasylol 60 minutes segment will follow a commercial.
If you or a loved one may have been injured by the use of Trasylol, you need a top Trasylol Injury Lawyer with the knowledge and experience to make sure you recover the compensation your deserve.
The Trasylol product liability lawyers at Trasylol-Injury-Lawyers.com have recovered over $900 million for our clients, including individual settlements over $10 million and class-wide settlements of over $90 million. Our top national Trasylol trial attorneys have won jury awards for injured individuals up to $105 million.
Kidney problems or kidney failure after CABG heart bypass surgery?
On dialysis?
Trasylol/Apropotinin to blame?
Not sure?
Knowledge is Power.
Contact us today for a free, private consultation.
Let our Trasylol Injury Lawyers get you the compensation you deserve.
800-845-6913
Trasylol Timeline: 1993-2008
December 30, 1993—Aprotinin, the scientific name for Trasylol, is awarded approval by the US Food and Drug Administration (FDA) to control excess bleeding in high-risk cardiac patients during surgery. It should be noted that some participants in clinical trials experienced kidney problems. Trasylol was approved anyway.
January 20, 2006—‘Transfusion’, a medical journal, publishes the findings of a study by Karkouti et al, which suggested an association between aprotinin and kidney problems amongst heart bypass patients.
January 26, 2006—Just six days later, the New England Journal of Medicine publishes the findings of yet another study, and this is the first time we hear the name of Dennis Mangano. The noted California-based researcher spent years studying aprotinin on behalf of a non-profit research institute, and concluded that Trasylol patients presented a 55 percent increase of heart failure and a whopping 181 per cent increase in stroke risk. Mangano’s study also found that aprotinin patients were more than twice as likely to experience kidney failure, requiring dialysis.
February 8, 2006—The FDA issues a public health warning, and schedules an advisory committee meeting in seven months to vet the study findings, and decide Trasylol’s ultimate fate. Unbeknownst to anyone, Trasylol manufacturer Bayer AG, headquartered in Germany, orders its own study in an attempt to verify, or disprove the findings of Mangano and Karkouti. That study is completed and delivered to Bayer in time for the advisory committee hearing.
September 21, 2006—The FDA convenes an Advisory Committee meeting to discuss Trasylol. Despite overwhelming evidence, the committee dismissed the findings of the two studies presented: Karkouti and Mangano et al, taking exception to the fact that Mangano’s exhaustive effort was an observational study, and not the gold standard of a clinical trial. Based on that, the Committee voted to support the existing safety and efficacy position on Trasylol and strongly supported its continuance. The third study funded by Bayer and supporting the findings of the other two, was never presented at the hearing. The author of the Bayer study, horrified that his report was not brought forward at the Advisory Committee hearing, approached the FDA.
September 27, 2006—Bayer AG formally reveals to the FDA the existence of its own observational study, which, like the previous two, revealed the risk for stroke, congestive heart failure, kidney damage and death.
September 29, 2006—The FDA reveals publicly that Bayer had failed to disclose the study, and issues a safety warning to the medical community. Bayer explains the oversight as a regrettable human error.
October 13, 2006—Bayer suspends two employees in what appears, it has been reported, an attempt to explain and justify the oversight. Bayer suggests initially that the report was withheld because it was preliminary in nature, but later admitted that the study should have been presented to the Advisory Committee panel, and it undertook the suspension of two Bayer employees. The FDA issues a safety warning.
December 15, 2006—Trasylol product labeling is strengthened on the basis of an ongoing FDA review of Trasylol commenced at the beginning of the year. Trasylol was mandated to carry a black box warning for the potential of kidney damage, and its use limited to certain situations.
September 12, 2007—Yet another FDA Advisory Panel convenes, this time with all study material in hand. Incredibly, however, the Review Panel concludes that the benefits of aprotinin continue to outweigh the risks, and Trasylol is allowed to continue.
November 5, 2007—Trasylol is finally taken off the market after a Canadian clinical trial was halted due to an alarming death rate amongst aprotinin patients. The FDA, Health Canada as well as the German health authority combined to urge Bayer to pull Trasylol. Bayer agreed, subject to analysis of the Canadian BART findings. Dr. Dennis Mangano estimates that 1,000 lives were lost each month to Trasylol, and over 20,000 lives in the nearly two years it took to finally pull Trasylol from the market.
February 17, 2008—The CBS news program 60 Minutes airs “A Thousand Lives a Month,” a segment featuring prominent Trasylol researcher Dr. Dennis Mangano, who revealed widespread fatalities associated with the heart surgery drug Trasylol and claims 22,000 people died because of the FDA’s delay in blowing the whistle on the drug after his study was published. Dr. Dennis Mangano admonished the FDA for waiting more than a year to pull Trasylol from the U.S. market, after it was banned in Germany. The segment reported that Bayer, Trasylol’s maker, failed to disclose negative results of its own study.
Mangano’s study associated the use of Trasylol to limit bleeding in heart surgery with kidney failure. In September 2006, when Mangano presented his study to the FDA, Bayer defended the use of Trasylol and failed to disclose the company’s own earlier research, which confirmed Mangano’s results. The FDA finally halted sales of Trasylol in November 2007.
February 21, 2008
The New England Journal of Medicine published two separate studies (The Harvard Study and the Duke Study) linking Trasylol use during open heart bypass surgery with increased risks of renal/kidney failure and death.
May 14, 2008
The New England Journal of Medicine published the Canada BART study, which had to be stopped during the clinical trial stage because of a higher rate of death in patients receiving Trasylol than an alternative anti-bleeding drug or none at all.
Trasylol Timeline: 1993-2008
December 30, 1993—Aprotinin, the scientific name for Trasylol, is awarded approval by the US Food and Drug Administration (FDA) to control excess bleeding in high-risk cardiac patients during surgery. It should be noted that some participants in clinical trials experienced kidney problems. Trasylol was approved anyway.
January 20, 2006—‘Transfusion’, a medical journal, publishes the findings of a study by Karkouti et al, which suggested an association between aprotinin and kidney problems amongst heart bypass patients.
January 26, 2006—Just six days later, the New England Journal of Medicine publishes the findings of yet another study, and this is the first time we hear the name of Dennis Mangano. The noted California-based researcher spent years studying aprotinin on behalf of a non-profit research institute, and concluded that Trasylol patients presented a 55 percent increase of heart failure and a whopping 181 per cent increase in stroke risk. Mangano’s study also found that aprotinin patients were more than twice as likely to experience kidney failure, requiring dialysis.
February 8, 2006—The FDA issues a public health warning, and schedules an advisory committee meeting in seven months to vet the study findings, and decide Trasylol’s ultimate fate. Unbeknownst to anyone, Trasylol manufacturer Bayer AG, headquartered in Germany, orders its own study in an attempt to verify, or disprove the findings of Mangano and Karkouti. That study is completed and delivered to Bayer in time for the advisory committee hearing.
September 21, 2006—The FDA convenes an Advisory Committee meeting to discuss Trasylol. Despite overwhelming evidence, the committee dismissed the findings of the two studies presented: Karkouti and Mangano et al, taking exception to the fact that Mangano’s exhaustive effort was an observational study, and not the gold standard of a clinical trial. Based on that, the Committee voted to support the existing safety and efficacy position on Trasylol and strongly supported its continuance. The third study funded by Bayer and supporting the findings of the other two, was never presented at the hearing. The author of the Bayer study, horrified that his report was not brought forward at the Advisory Committee hearing, approached the FDA.
September 27, 2006—Bayer AG formally reveals to the FDA the existence of its own observational study, which, like the previous two, revealed the risk for stroke, congestive heart failure, kidney damage and death.
September 29, 2006—The FDA reveals publicly that Bayer had failed to disclose the study, and issues a safety warning to the medical community. Bayer explains the oversight as a regrettable human error.
October 13, 2006—Bayer suspends two employees in what appears, it has been reported, an attempt to explain and justify the oversight. Bayer suggests initially that the report was withheld because it was preliminary in nature, but later admitted that the study should have been presented to the Advisory Committee panel, and it undertook the suspension of two Bayer employees. The FDA issues a safety warning.
December 15, 2006—Trasylol product labeling is strengthened on the basis of an ongoing FDA review of Trasylol commenced at the beginning of the year. Trasylol was mandated to carry a black box warning for the potential of kidney damage, and its use limited to certain situations.
September 12, 2007—Yet another FDA Advisory Panel convenes, this time with all study material in hand. Incredibly, however, the Review Panel concludes that the benefits of aprotinin continue to outweigh the risks, and Trasylol is allowed to continue.
November 5, 2007—Trasylol is finally taken off the market after a Canadian clinical trial was halted due to an alarming death rate amongst aprotinin patients. The FDA, Health Canada as well as the German health authority combined to urge Bayer to pull Trasylol. Bayer agreed, subject to analysis of the Canadian BART findings. Dr. Dennis Mangano estimates that 1,000 lives were lost each month to Trasylol, and over 20,000 lives in the nearly two years it took to finally pull Trasylol from the market.
February 17, 2008—The CBS news program 60 Minutes airs “A Thousand Lives a Month,” a segment featuring prominent Trasylol researcher Dr. Dennis Mangano, who revealed widespread fatalities associated with the heart surgery drug Trasylol and claims 22,000 people died because of the FDA’s delay in blowing the whistle on the drug after his study was published. Dr. Dennis Mangano admonished the FDA for waiting more than a year to pull Trasylol from the U.S. market, after it was banned in Germany. The segment reported that Bayer, Trasylol’s maker, failed to disclose negative results of its own study.
Mangano’s study associated the use of Trasylol to limit bleeding in heart surgery with kidney failure. In September 2006, when Mangano presented his study to the FDA, Bayer defended the use of Trasylol and failed to disclose the company’s own earlier research, which confirmed Mangano’s results. The FDA finally halted sales of Trasylol in November 2007.
February 21, 2008
The New England Journal of Medicine published two separate studies (The Harvard Study and the Duke Study) linking Trasylol use during open heart bypass surgery with increased risks of renal/kidney failure and death.
May 14, 2008
The New England Journal of Medicine published the Canada BART study, which had to be stopped during the clinical trial stage because of a higher rate of death in patients receiving Trasylol than an alternative anti-bleeding drug or none at all.
ABSTRACT
Background Antifibrinolytic agents are commonly used during cardiac surgery to minimize bleeding and to reduce exposure to blood products. We sought to determine whether aprotinin was superior to either tranexamic acid or aminocaproic acid in decreasing massive postoperative bleeding and other clinically important consequences.
Methods In this multicenter, blinded trial, we randomly assigned 2331 high-risk cardiac surgical patients to one of three groups: 781 received aprotinin, 770 received tranexamic acid, and 780 received aminocaproic acid. The primary outcome was massive postoperative bleeding. Secondary outcomes included death from any cause at 30 days.
Results The trial was terminated early because of a higher rate of death in patients receiving aprotinin. A total of 74 patients (9.5%) in the aprotinin group had massive bleeding, as compared with 93 (12.1%) in the tranexamic acid group and 94 (12.1%) in the aminocaproic acid group (relative risk in the aprotinin group for both comparisons, 0.79; 95% confidence interval [CI], 0.59 to 1.05). At 30 days, the rate of death from any cause was 6.0% in the aprotinin group, as compared with 3.9% in the tranexamic acid group (relative risk, 1.55; 95% CI, 0.99 to 2.42) and 4.0% in the aminocaproic acid group (relative risk, 1.52; 95% CI, 0.98 to 2.36). The relative risk of death in the aprotinin group, as compared with that in both groups receiving lysine analogues, was 1.53 (95% CI, 1.06 to 2.22).
Conclusions Despite the possibility of a modest reduction in the risk of massive bleeding, the strong and consistent negative mortality trend associated with aprotinin, as compared with the lysine analogues, precludes its use in high-risk cardiac surgery. (Current Controlled Trials number, ISRCTN15166455)
Continue reading A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery online at http://content.nejm.org/cgi/content/full/NEJMoa0802395
ABSTRACT
Background Antifibrinolytic agents are commonly used during cardiac surgery to minimize bleeding and to reduce exposure to blood products. We sought to determine whether aprotinin was superior to either tranexamic acid or aminocaproic acid in decreasing massive postoperative bleeding and other clinically important consequences.
Methods In this multicenter, blinded trial, we randomly assigned 2331 high-risk cardiac surgical patients to one of three groups: 781 received aprotinin, 770 received tranexamic acid, and 780 received aminocaproic acid. The primary outcome was massive postoperative bleeding. Secondary outcomes included death from any cause at 30 days.
Results The trial was terminated early because of a higher rate of death in patients receiving aprotinin. A total of 74 patients (9.5%) in the aprotinin group had massive bleeding, as compared with 93 (12.1%) in the tranexamic acid group and 94 (12.1%) in the aminocaproic acid group (relative risk in the aprotinin group for both comparisons, 0.79; 95% confidence interval [CI], 0.59 to 1.05). At 30 days, the rate of death from any cause was 6.0% in the aprotinin group, as compared with 3.9% in the tranexamic acid group (relative risk, 1.55; 95% CI, 0.99 to 2.42) and 4.0% in the aminocaproic acid group (relative risk, 1.52; 95% CI, 0.98 to 2.36). The relative risk of death in the aprotinin group, as compared with that in both groups receiving lysine analogues, was 1.53 (95% CI, 1.06 to 2.22).
Conclusions Despite the possibility of a modest reduction in the risk of massive bleeding, the strong and consistent negative mortality trend associated with aprotinin, as compared with the lysine analogues, precludes its use in high-risk cardiac surgery. (Current Controlled Trials number, ISRCTN15166455)
Continue reading A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery online at http://content.nejm.org/cgi/content/full/NEJMoa0802395
Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death, N Engl J Med. 2008 Feb 21;358(8):771-783.
Bayer Pharmaceuticals, the maker of Trasylol (aprotinin), financed a study conducted at Harvard University in which the medical records of 78,000 heart surgery patients were reviewed to investigate “accumulating evidence” suggesting the use of Trasylol during coronary-artery bypass surgery increases the risk of death.
The Trasylol researchers at Harvard studied the medical records of 78,000 patients who underwent coronary-artery bypass graft (CABG) surgery between January 1, 2003 to March 31, 2006. About 33,500 of the patients were given Trasylol (aprotinin injection) and 44,482 were given a different anti-bleeding medicine.
After statistical adjustment for 41 characteristics of patients and hospitals, the Bayer-financed, Harvard University researches concluded that the risk of death was 64% higher for the patients given Trasylol compared with those given a different drug.
Bayer had the details of the Harvard study when it appeared for FDA hearings on Trasylol in September 2006, but withheld the results of the study from the FDA. As a result, Trasylol remained on the market for another 22 months.
The effect of aprotinin on outcome after coronary-artery bypass grafting, N Engl J Med. 2008 Feb 21;358(8):784-93.
In 2006, a study published in the New England Journal of Medicine linked Trasylol use during heart surgery with an increased the risk of heart attack, stroke, kidney damage, renal failure, and death.
In response, researchers at Duke University reviewed the cases of over 10,000 patients who underwent coronary-artery bypass graft (CABG) surgery at Duke University Medical Center between January 1, 1996 and December 31, 2005. The purpose of the study was to look for an association between Trasylol (aprotinin) use and adverse outcomes including those reported in the 2006 study (heart attack, stroke, kidney damage, renal failure, and death.)
The Duke Study found that the 30-day death rate of patients given Trasylol during coronary-artery bypass grafting (CABG) surgery is nearly 250% higher than CABG patients given another anti-bleeding drug or no drug at all. The study also linked Trasylol with an increased risk of kidney damage and impaired kidney function.
“We’re not surprised by the results,” says Dr. Andrew Shaw, Associate Professor of Medicine at Duke and lead author of the study. “It’s what we expected to find.”